HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness of slow-release systems in CD40 agonistic antibody immunotherapy of cancer.

Abstract
Slow-release delivery has great potential for specifically targeting immune-modulating agents into the tumor-draining area. In prior work we showed that local treatment of slowly delivered anti-CD40 antibody induced robust anti-tumor CD8+ T cell responses without systemic toxicity. We now report on the comparison of two slow-release delivery systems for their use in antibody-based immunotherapy of cancer. Anti-CD40 agonistic antibody delivered locally in mineral oil Montanide ISA 51 or in dextran-based microparticles activated tumor-specific T cell activation. Both slow-release formulations significantly decreased systemic side-effects compared to systemic administration of anti-CD40 antibody. However, dextran-based microparticles caused serious local inflammation associated with unwanted rapid outgrowth of tumors instead of the tumor clearance observed with delivery in Montanide. We therefore conclude that Montanide ISA 51 is to be preferred as a slow-release agent for CD40 agonist immunotherapy of cancer.
AuthorsMarieke F Fransen, Robert A Cordfunke, Marjolein Sluijter, Mies J van Steenbergen, Jan W Drijfhout, Ferry Ossendorp, Wim E Hennink, Cornelis J M Melief
JournalVaccine (Vaccine) Vol. 32 Issue 15 Pg. 1654-60 (Mar 26 2014) ISSN: 1873-2518 [Electronic] Netherlands
PMID24508038 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • CD40 Antigens
  • Delayed-Action Preparations
  • Dextrans
  • Oleic Acids
  • montanide ISA 51
  • Mannitol
Topics
  • Animals
  • Antibodies, Monoclonal (immunology, pharmacokinetics, therapeutic use)
  • CD40 Antigens (agonists, immunology)
  • CD8-Positive T-Lymphocytes (immunology)
  • Delayed-Action Preparations (pharmacokinetics, therapeutic use)
  • Dextrans (pharmacokinetics)
  • Hybridomas (immunology)
  • Immunotherapy
  • Male
  • Mannitol (analogs & derivatives, pharmacokinetics)
  • Mice
  • Mice, Inbred C57BL
  • Neoplasms, Experimental (therapy)
  • Oleic Acids (pharmacokinetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: